Verition Fund Management
ESPR icon

Verition Fund Management’s Esperion Therapeutics ESPR Stock Holding History

Verition Fund Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-41,000
Closed -$110K – 3060
2024
Q1 		$110K Buy
+41,000
New +$99.6K ﹤0.01% 2574

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Verition Fund Management's ESPR Position: Q2 2026 in Review

Verition Fund Management opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 502,200 shares worth $1.59M. The stake represents 0.01% of the portfolio and ranks #1213 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in ESPR as recently as Q4 2025.

Verition Fund Management first reported a position in ESPR in Q2 2019 and has held it in 17 quarters since. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Verition Fund Management held 502,200 shares of Esperion Therapeutics worth $1.59M as of Q2 2026.
  • Esperion Therapeutics was a new Verition Fund Management position in Q2 2026.
  • Esperion Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1213 holding.
  • Verition Fund Management first reported a position in Esperion Therapeutics in Q2 2019 and has held it in 17 quarters since.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.